Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Status:
Suspended
Trial end date:
2022-03-02
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of venetoclax when given
together with ixazomib citrate and dexamethasone and to see how well they work in treating
patients with multiple myeloma that has come back. Venetoclax and ixazomib citrate may stop
the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used
in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving venetoclax together with ixazomib citrate and dexamethasone may work better
in treating patients with multiple myeloma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
Multiple Myeloma Research Foundation National Cancer Institute (NCI)